Latham Recognized With Two Awards From LMG Life Sciences
Firm awarded for excellence and innovation in the life science legal space.
Ben Haas, Global Vice Chair of the Healthcare & Life Sciences Practice, advises clients across all stages of pre- and post-market US Food and Drug Administration (FDA) regulation and compliance.
Ben leverages extensive experience and a sophisticated understanding of FDA-regulated products to guide medical device, pharmaceutical, biotechnology, tobacco, food, cosmetic, and dietary supplement companies on:
Ben advises on corporate compliance, mergers and acquisitions, and other corporate transactions, and counsels on legislative and administrative rulemaking proceedings relating to healthcare government mandates.
Ben also counsels clients on compliance and regulatory matters arising under the Consumer Product Safety Act (CPSA) and other statutes administered by the US Consumer Product Safety Commission (CPSC). He also helps clients design and implement product recalls within the CPSC’s jurisdiction.
A recognized thought leader and member of the FDA bar, Ben regularly speaks on FDA regulatory and enforcement matters and has served on multiple committees for the Food and Drug Law Institute.
Ben counsels FDA-regulated device companies on:
Firm awarded for excellence and innovation in the life science legal space.